by Stephen Levin
John Simpson, MD, PhD, has always had a contrarian's view of atherosclerotic plaque. Based on his pioneering work in angioplasty...
FoxHollow and Merck Expand Alliance, Aim at Vulnerable Plaque
What's the value of a well-documented set of clinical samples in the atherosclerosis business? For Merck, about $150 million. For FoxHollow, funding and validation for its contrarian device model.